Correlation Between Arcellx and Phathom Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Arcellx and Phathom Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arcellx and Phathom Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Arcellx and Phathom Pharmaceuticals, you can compare the effects of market volatilities on Arcellx and Phathom Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arcellx with a short position of Phathom Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arcellx and Phathom Pharmaceuticals.
Diversification Opportunities for Arcellx and Phathom Pharmaceuticals
-0.42 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Arcellx and Phathom is -0.42. Overlapping area represents the amount of risk that can be diversified away by holding Arcellx and Phathom Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Phathom Pharmaceuticals and Arcellx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arcellx are associated (or correlated) with Phathom Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Phathom Pharmaceuticals has no effect on the direction of Arcellx i.e., Arcellx and Phathom Pharmaceuticals go up and down completely randomly.
Pair Corralation between Arcellx and Phathom Pharmaceuticals
Given the investment horizon of 90 days Arcellx is expected to generate 0.57 times more return on investment than Phathom Pharmaceuticals. However, Arcellx is 1.75 times less risky than Phathom Pharmaceuticals. It trades about 0.09 of its potential returns per unit of risk. Phathom Pharmaceuticals is currently generating about -0.16 per unit of risk. If you would invest 7,427 in Arcellx on September 7, 2024 and sell it today you would earn a total of 1,215 from holding Arcellx or generate 16.36% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Arcellx vs. Phathom Pharmaceuticals
Performance |
Timeline |
Arcellx |
Phathom Pharmaceuticals |
Arcellx and Phathom Pharmaceuticals Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Arcellx and Phathom Pharmaceuticals
The main advantage of trading using opposite Arcellx and Phathom Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arcellx position performs unexpectedly, Phathom Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phathom Pharmaceuticals will offset losses from the drop in Phathom Pharmaceuticals' long position.Arcellx vs. Nuvalent | Arcellx vs. Ventyx Biosciences | Arcellx vs. Amylyx Pharmaceuticals | Arcellx vs. Day One Biopharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Complementary Tools
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |